Basic Information
VYVANSE CAPSULES 20 mg
CAPSULE
Regulatory Information
SIN15840P
November 1, 2019
Prescription Only
Therapeutic
ORAL
August 10, 2023
May 30, 2025
XN06BA12
Company Information
TAKEDA PHARMACEUTICALS (ASIA PACIFIC) PTE. LTD.
TAKEDA PHARMACEUTICALS (ASIA PACIFIC) PTE. LTD.
Active Ingredients
Strength: 20.0 mg
Detailed Information
Contraindications
**4 CONTRAINDICATIONS** VYVANSE is contraindicated in patients with: - Known hypersensitivity to amphetamine products or other ingredients of VYVANSE. Anaphylactic reactions, Stevens-Johnson Syndrome, angioedema, and urticaria have been observed in post-marketing reports _\[see Adverse Reactions (6.2)_ – _please refer to the Product Insert/Patient Information Leaflet published on HSA for the full drug information_ _\]_. - Patients taking monoamine oxidase inhibitors (MAOIs), or within 14 days of stopping MAOIs (including MAOIs such as linezolid or intravenous methylene blue), because of an increased risk of hypertensive crisis _\[see Warnings and Precautions (5.7) and Drug Interactions (7.1)_ – _please refer to the Product Insert/Patient Information Leaflet published on HSA for the full drug information_ _\]_.
Indication Information
**1 INDICATIONS AND USAGE** VYVANSE® is indicated for the treatment of: - Attention Deficit Hyperactivity Disorder (ADHD) _\[see Clinical Studies (14)_ – _please refer to the Product Insert/Patient Information Leaflet published on HSA for the full drug information_ _\]_ Limitation of Use: VYVANSE is not indicated or recommended for weight loss. Use of other sympathomimetic drugs for weight loss has been associated with serious cardiovascular adverse events. The safety and effectiveness of VYVANSE for the treatment of obesity have not been established _\[see Warnings and Precautions (5.2)_ – _please refer to the Product Insert/Patient Information Leaflet published on HSA for the full drug information_ _\]_.